Xianxian Zheng Selected Research

nirogacestat

3/2015	PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a γ-secretase inhibitor.
1/2015	A Phase I, dose-finding study in patients with advanced solid malignancies of the oral γ-secretase inhibitor PF-03084014.
9/2012	Biomarker and pharmacologic evaluation of the γ-secretase inhibitor PF-03084014 in breast cancer models.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Xianxian Zheng Research Topics

Disease

9	Neoplasms (Cancer) 08/2019 - 03/2012
2	Disease Progression 01/2016 - 08/2015
2	Breast Neoplasms (Breast Cancer) 03/2015 - 09/2012
1	Aortic Diseases 01/2022
1	Bites and Stings (Sting) 01/2022
1	Non-alcoholic Fatty Liver Disease 01/2022
1	Obesity 01/2022
1	Myocardial Infarction 01/2022
1	Metabolic Diseases (Metabolic Disease) 01/2022
1	Aneurysm (Aneurysms) 01/2022
1	Heart Failure 01/2022
1	Cardiomegaly (Heart Hypertrophy) 01/2022
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2020
1	Cardiotoxicity 01/2020
1	Stomach Neoplasms (Stomach Cancer) 08/2019
1	Hematologic Neoplasms (Hematological Malignancy) 08/2017
1	Spasm (Spasms) 08/2017
1	Glioma (Gliomas) 08/2017
1	Alopecia (Baldness) 08/2017
1	Dysgeusia (Parageusia) 08/2017
1	Diarrhea 08/2017
1	Constipation 08/2017
1	Colorectal Neoplasms (Colorectal Cancer) 01/2016
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 08/2015
1	Primary Myelofibrosis (Myelosclerosis) 08/2015
1	Triple Negative Breast Neoplasms 03/2015
1	Neoplasm Metastasis (Metastasis) 09/2012
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 03/2012
1	Colonic Neoplasms (Colon Cancer) 03/2012
1	Retinoblastoma (Glioblastoma, Retinal) 03/2012
1	Respiratory Syncytial Virus Infections 04/2009
1	Pulmonary Hypertension 02/2006
1	Type 2 Diabetes Mellitus (MODY) 04/2003

Drug/Important Bio-Agent (IBA)

4	Biomarkers (Surrogate Marker)IBA 01/2016 - 03/2012
3	glasdegibIBA 08/2017 - 01/2015
3	nirogacestatIBA 03/2015 - 09/2012
3	Amyloid Precursor Protein Secretases (beta-Secretase)IBA 03/2015 - 09/2012
2	LigandsIBA 12/2018 - 01/2016
1	cyclic guanosine monophosphate-adenosine monophosphateIBA 01/2022
1	CytokinesIBA 01/2022
1	DNA (Deoxyribonucleic Acid)IBA 01/2022
1	Mitochondrial DNA (mtDNA)IBA 01/2022
1	InterferonsIBA 01/2022
1	Interferon Type IIBA 01/2022
1	radix ophiopogonis drug combination radix ginseng fructus schizandrae (Shen Mai)IBA 01/2020
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2020
1	Cisplatin (Platino)FDA LinkGeneric 08/2019
1	MicroRNAs (MicroRNA)IBA 08/2019
1	KynurenineIBA 12/2018
1	PF-06840003IBA 12/2018
1	Blocking AntibodiesIBA 12/2018
1	CreatinineIBA 08/2017
1	Indicators and Reagents (Reagents)IBA 01/2016
1	Notch1 ReceptorIBA 01/2016
1	Notch ReceptorsIBA 03/2015
1	Insulin Receptor Substrate ProteinsIBA 12/2013
1	Insulin-Like PeptidesIBA 12/2013
1	Insulin-Like Growth Factor Binding Protein 5IBA 12/2013
1	figitumumabIBA 12/2013
1	Messenger RNA (mRNA)IBA 09/2012
1	Aurora Kinase BIBA 03/2012
1	Aurora Kinase AIBA 03/2012
1	N- (2- (6- (4- cyclobutylamino- 5- trifluoromethylpyrimidine- 2- ylamino)- 1,2,3,4- tetrahydro- 1,4- epiazano- naphthalen- 9- yl)- 2- oxo- ethyl)acetamideIBA 03/2012
1	Pharmaceutical PreparationsIBA 03/2012
1	VaccinesIBA 04/2009
1	Glycoproteins (Glycoprotein)IBA 04/2009
1	Endothelin A ReceptorIBA 02/2006
1	PD 180988IBA 02/2006
1	ThiazolidinedionesIBA 04/2003
1	Rosiglitazone (Avandia)FDA Link 04/2003
1	Pioglitazone (Actos)FDA Link 04/2003

Therapy/Procedure

1	Drug Therapy (Chemotherapy) 01/2022
1	Combination Drug Therapy (Combination Chemotherapy) 08/2019
1	Therapeutics 12/2018
1	Immunotherapy 12/2018
1	Oral Administration 01/2015
1	Aftercare (After-Treatment) 09/2012